ADAGIO MEDICAL HOLDINGS INC
ADGMNASDAQTrading Snapshot
- Day Range
- $0.15 – $0.15
- 52-Week Range
- $0.18 – $2.58
- Volume
- $2.44B
- Avg Volume
- $2.64B
- Shares Outstanding
- 22.2M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $621,057
- Last Q Revenue
- $152,654
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.44
- Dividend Yield
- —
- Dilution (1yr)
- +35.5%
Why Investors Own ADGM
- ✓High-growth profile — revenue up +11.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ADAGIO MEDICAL HOLDINGS INC
ADGM
StockOtter · stockotter.spaceAbout ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing the treatment of cardiac arrhythmias through advanced medical technologies. Utilizing its proprietary platform, the company is spearheading the development of targeted ablation techniques that address significant unmet needs in the electrophysiology sector. Supported by a robust product pipeline and a seasoned leadership team, Adagio represents an attractive investment opportunity for institutional investors seeking growth in the healthcare space while contributing to improved outcomes in cardiac patient care.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Adagio Medical Announces Strategic Review Process to Maximize Shareholder Value
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today annou
Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner -- University Medical Center Phoenix
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (âAdagioâ or âthe Companyâ), a leading innovator in catheter ablation technologies for the treatment of car
Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac ar
Adagio Medical Reports Second Quarter 2026 Results
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac ar
Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac ar
Robo.ai Announces Core Executive Appointments, Forming a Local UAE Leadership Team at Neurovia AI
Robo.ai Announces Core Executive Appointments, Forming a Local UAE Leadership Team at Neurovia AI PR Newswire AB